There is no doubt that artificial intelligence (AI) and other advanced technologies (AT) will add significant value to global regulatory practices over time. However, it is still unclear how and when integration to a trusted level with attractive business benefits will be achieved for most organisations.

This article reports on the results and insights of two recent Gens & Associates surveys that explored advanced technology status, investment priorities, industry and software provider readiness / maturity, and data governance practices for the regulatory function of biopharmaceutical and medical device companies.